Anti-VEGF treatment in branch retinal vein occlusion: A real-world experience over 4 years

Acta Ophthalmologica

Volumn 93, Issue 8, 2015, Pages 719-725

  Rezar, Sandra ^a   Eibenberger, Katharina ^a   Bühl, Wolf ^a   Georgopoulos, Michael ^a   Schmidt Erfurth, Ursula ^a   Sacu, Stefan ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

antivascular endothelial growth factor; branch retinal vein occlusion; long term outcome; macular oedema

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; CENTRAL RETINAL SENSITIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONVALESCENCE; CROSS-SECTIONAL STUDY; DRUG DOSE REDUCTION; EARLY INTERVENTION; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MACULAR EDEMA; MICROANGIOPATHY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETINA VEIN OCCLUSION; RETINAL THICKNESS; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG EFFECTS; FEMALE; INTRAVITREAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; RETINAL VEIN OCCLUSION; RETREATMENT;

AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; CROSS-SECTIONAL STUDIES; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; RETINAL VEIN OCCLUSION; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84955740604     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12772     Document Type: Article

References (23)

1. Bertelsen M, Linneberg A, Rosenberg T, et al., (2012): Comorbidity in patients with branch retinal vein occlusion: case-control study. BMJ 345: e7885.
2. Bezatis A, Spital G, Höhn F, et al., (2013): Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up-the SOLO study. Acta Ophthalmol 91: e340-e347.
3. Brown DM, Campochiaro PA, Bhisitkul RB, et al., (2011): Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118: 1594-1602.
4. Campochiaro PA, Heier JS, Feiner L, et al., (2010a): Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117: 1102-1112.
5. Campochiaro PA, Hafiz G, Channa R, et al., (2010b): Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes. Ophthalmology 117: 2387-2394.
6. David R, Zangwill L, Badarna M, et al., (1988): Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica 197: 69-74.
7. Elman MJ, Bhatt AK, Quinlan PM, et al., (1990): The risk for systemic vascular diseases and mortality in patients with central retinal vein occlusion. Ophthalmology 97: 1543-1548.
8. Ferrara DC, Koizumi H, &, Spaide RF, (2007): Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 144: 864-871.
9. Greer DV, Constable IJ, &, Cooper RL, (1980): Macular oedema and retinal branch vein occlusion. Aust J Ophthalmol 8: 207-209.
10. Jaissle GB, Szurman P, Feltgen N, et al., (2011): Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 249: 183-192.
11. Klein R, Klein BE, Moss SE, et al., (2000): The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 98: 133-141.
12. Pece A, Isola V, Piermarocchi S, et al., (2011): fficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up. Br J Ophthalmol 95: 56-68.
13. Pielen A, Mirshahi A, Feltgen N, et al., (2015): Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmol 93: e29-e37.
14. Prager F, Michels S, Kriechbaum K, et al., (2009): Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 93: 452-456.
15. Rehak M, Tilgner E, Franke A, et al., (2014): Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (results of a proof of concept study). Graefes Arch Clin Exp Ophthalmol 252: 745-752.
16. Rensch F, Jonas JB, &, Spandau UH, (2009): Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion. Ophthalmologica 223: 124-127.
17. Rogers SL, McIntosh RL, Lim L, et al., (2010): Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117: 1094-1101.
18. Sacu S, Pemp B, Weigert G, et al., (2011): Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion. Invest Ophthalmol Vis Sci 52: 3046-3050.
19. Sohn HJ, Han DH, Lee DY, et al., (2014): Changes in aqueous cytokines after intravitreal triamcinolone versus bevacizumab for macular oedema in branch retinal vein occlusion. Acta Ophthalmol 92: e217-e224.
20. Spaide RF, (2013): Prospective study of peripheral panretinal photo-coagulation of areas of nonperfusion in central retinal vein occlusion. Retina 33: 56-62.
21. Thach AB, Yau L, Hoang C, et al., (2014): Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. Ophthalmology 21: 1059-1066.
22. Varma R, Bressler NM, Suñer I, et al., (2012): Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology 119: 2108-2118.
23. Yilmaz T, &, Cordero-Coma M, (2012): Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review. Graefes Arch Clin Exp Ophthalmol 250: 787-793.